- Email: [email protected]
P0190Colorectal cancer in Niger: An analysis of the Niger Cancer Registry Data
Abstracts / 50 (2014) e1–e74
Background: Patients with recurrences after primary chemoradiation are the most difficult group to be treated by head and neck oncologists. After the use of chemotherapy and radiation, surgery can rescue outcomes. But during salvage surgeries, major resections have to be contemplated that require large-volume reconstructive procedures. Pectoralis major myocutaneous flap (PMMCF) reconstruction is an ideal flap for this scenario. We aimed to assess the usefulness of PMMCF in reconstruction after major head and neck resections during salvage surgery. Methods: For 48 months, we studied 136 patients with recurrences of head and neck cancers after primary chemoradiation. Patients underwent major head and neck resections followed by immediate reconstruction with PMMCF. Outcomes were quality of life, oncological safety, and cosmetic outcomes after reconstruction with PMMCF. We assessed oncological safety with margin status; cosmetic outcome with photographs taken at 1 month, 3 months, 6 months and 1 year; and personal experience and quality of life with a questionnaire. Findings: The age range of patients was 31–72 years. Operating time ranged from 130 min to 210 min (mean 153.9). Blood loss ranged from 75 mL to 300 mL (mean 134 mL). The skin island used for volume replacement ranged from 4 cm by 3 cm to 10 cm by 6 cm. No patient had margin positivity or close margins. Three patients had major wound complications and five had minor wound complications. Five patients developed a fistula and five had flap loss. The follow-up period ranged from 12 months to 23 months. For quality of life score, 86% of patients gave a satisfactory score. Interpretation: PMMC is an ideal flap with good cosmetic outcomes, oncological safety, and quality of life outcomes. Its usefulness can be extended to major head and neck resections in salvage surgeries.
http://dx.doi.org/10.1016/j.ejca.2014.03.228
P0185 MOLECULAR MECHANISMS OF A NOVEL IMIDAZOPYRIDINE CDK-INHIBITOR ALONE AND IN COMBINATION WITH DOXORUBICIN R.A.E. El-Awady *, M.M. Saber, M.H. Semreen, T. Tl-Tel, S.M.E. El-Ansassy, R.A. Sahib, S. Hassan, M. Rahimi, D. El-Wahiby, Y. Deire. College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates Background: Dysregulation of the mechanisms that control normal cell cycle progression is a prominent characteristic of cancer cells. Cyclin-dependent kinases (Cdks) are molecules that facilitate the progression of the cell cycle by binding to cyclins and phosphorylating downstream proteins that assist in cell cycle propagation. Cdk inhibitors have been reported as valuable agents for cancer therapy because of their role in inhibition of cell proliferation and induction of apoptosis. Methods: We investigated the cytotoxic effects of a newly designed Cdk inhibitor, an imidazopyridine derivative, alone and in combination with other anticancer drugs in three cancer cell lines (MCF7, A549, and M8). In addition, we investigated the effect of this new compound on induction of apoptosis, DNA damage, and repair and cell cycle progression. Findings: This compound is more cytotoxic against the lung cancer cell line (A549) than against other cell lines. It enhanced the cytotoxic effects of doxorubicin in A549 cells. Mechanistic investigations showed that the drug inhibits A549 cells from crossing the G1–S checkpoint and arrests cells at the G1 phase of the cell cycle. The drug induces
e63
caspase-3 activity in a concentration and time dependent manner. Combination of this compound with the anticancer drug doxorubicin showed inhibition of the repair of doxorubicin-induced DNA damage. Interpretation: These results indicate that the newly designed compound is promising, and could enhance the cytotoxicity of other anticancer agents.
http://dx.doi.org/10.1016/j.ejca.2014.03.229
P0190 COLORECTAL CANCER IN NIGER: AN ANALYSIS OF THE NIGER CANCER REGISTRY DATA S.M. Garba a,b, H. Hami a,*, H.M. Zaki b, A. Soulaymani a, H. Nouhou b, A. Quyou a . a Laboratory of Genetics and Biometry, Faculty of Science, Ibn Tofaı¨l University, Kenitra, Morocco, b Laboratory of Pathological Anatomy and Cytology, Faculty of Health Sciences, Abdou Moumouni University, Niamey, Niger Background: Colorectal cancer is a major cause of morbidity and mortality in the world, accounting for 9.7% of all cancers. It is the third most common diagnosed cancer and the fourth leading cause of cancer-related death worldwide, causing an estimated 1.36 million new cancer cases and 694,000 deaths in 2012. We aimed to determine the epidemiological characteristics of colorectal cancer in Niger. Methods: This is a retrospective analysis of colorectal cancer cases, reported between 1992 and 2009 to the Niger Cancer Registry, established in 1992, in the Faculty of Health Sciences at the Abdou Moumouni University in Niamey, Niger. Findings: There were 349 cases diagnosed with colorectal cancer in Niger (51% of cases in the rectum and 49% in the colon), which was 4.96% of all cancers reported during the study period. Nearly 62% of the cases were in men, with a male–female ratio of 1.6. The average age at diagnosis was 46.8 ± 15.4 years. More than three-quarters (76.8%) of people diagnosed with the disease were older than 35 years at the time of diagnosis, with 63% of new cancer cases occurring in those aged 35–64 years. The highest rates for women were noted in those aged 40–69 years (62.7%) and rates for men highest between aged 35–69 years (71.2%). The risk of development of colorectal cancer varied among various ethnic groups. Djerma Sonrai was more likely to develop colorectal cancer (55%) than were any other ethnic groups, followed by Haoussa (29.5%) and Touareg (6.6%). Most colorectal cancers were adenocarcinomas and 8.6% of individuals died during the study period, accounting for 3.3% of all cancer deaths. Interpretation: Despite the limitations of the available data, it is clear that there are several barriers in access to cancer control in developing countries.
http://dx.doi.org/10.1016/j.ejca.2014.03.234
P0191 RADIATION THERAPY FOR BILIARY TRACT TUMOURS: JOINT EXPERIENCE OF THREE CENTRES M.S. Karabey a, E.Y. Erkal a, A. Yolcu b, B.H. Bakkal c, B. Sarper a, G. Aksu a, H.S. Erkal d,*. a Department of Radiation Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey, b Department of Radiation Oncology, Selcuk University Faculty of Medicine,
Background: Patients with recurrences after primary chemoradiation are the most difficult group to be treated by head and neck oncologists. After the use of chemotherapy and radiation, surgery can rescue outcomes. But during salvage surgeries, major resections have to be contemplated that require large-volume reconstructive procedures. Pectoralis major myocutaneous flap (PMMCF) reconstruction is an ideal flap for this scenario. We aimed to assess the usefulness of PMMCF in reconstruction after major head and neck resections during salvage surgery. Methods: For 48 months, we studied 136 patients with recurrences of head and neck cancers after primary chemoradiation. Patients underwent major head and neck resections followed by immediate reconstruction with PMMCF. Outcomes were quality of life, oncological safety, and cosmetic outcomes after reconstruction with PMMCF. We assessed oncological safety with margin status; cosmetic outcome with photographs taken at 1 month, 3 months, 6 months and 1 year; and personal experience and quality of life with a questionnaire. Findings: The age range of patients was 31–72 years. Operating time ranged from 130 min to 210 min (mean 153.9). Blood loss ranged from 75 mL to 300 mL (mean 134 mL). The skin island used for volume replacement ranged from 4 cm by 3 cm to 10 cm by 6 cm. No patient had margin positivity or close margins. Three patients had major wound complications and five had minor wound complications. Five patients developed a fistula and five had flap loss. The follow-up period ranged from 12 months to 23 months. For quality of life score, 86% of patients gave a satisfactory score. Interpretation: PMMC is an ideal flap with good cosmetic outcomes, oncological safety, and quality of life outcomes. Its usefulness can be extended to major head and neck resections in salvage surgeries.
http://dx.doi.org/10.1016/j.ejca.2014.03.228
P0185 MOLECULAR MECHANISMS OF A NOVEL IMIDAZOPYRIDINE CDK-INHIBITOR ALONE AND IN COMBINATION WITH DOXORUBICIN R.A.E. El-Awady *, M.M. Saber, M.H. Semreen, T. Tl-Tel, S.M.E. El-Ansassy, R.A. Sahib, S. Hassan, M. Rahimi, D. El-Wahiby, Y. Deire. College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates Background: Dysregulation of the mechanisms that control normal cell cycle progression is a prominent characteristic of cancer cells. Cyclin-dependent kinases (Cdks) are molecules that facilitate the progression of the cell cycle by binding to cyclins and phosphorylating downstream proteins that assist in cell cycle propagation. Cdk inhibitors have been reported as valuable agents for cancer therapy because of their role in inhibition of cell proliferation and induction of apoptosis. Methods: We investigated the cytotoxic effects of a newly designed Cdk inhibitor, an imidazopyridine derivative, alone and in combination with other anticancer drugs in three cancer cell lines (MCF7, A549, and M8). In addition, we investigated the effect of this new compound on induction of apoptosis, DNA damage, and repair and cell cycle progression. Findings: This compound is more cytotoxic against the lung cancer cell line (A549) than against other cell lines. It enhanced the cytotoxic effects of doxorubicin in A549 cells. Mechanistic investigations showed that the drug inhibits A549 cells from crossing the G1–S checkpoint and arrests cells at the G1 phase of the cell cycle. The drug induces
e63
caspase-3 activity in a concentration and time dependent manner. Combination of this compound with the anticancer drug doxorubicin showed inhibition of the repair of doxorubicin-induced DNA damage. Interpretation: These results indicate that the newly designed compound is promising, and could enhance the cytotoxicity of other anticancer agents.
http://dx.doi.org/10.1016/j.ejca.2014.03.229
P0190 COLORECTAL CANCER IN NIGER: AN ANALYSIS OF THE NIGER CANCER REGISTRY DATA S.M. Garba a,b, H. Hami a,*, H.M. Zaki b, A. Soulaymani a, H. Nouhou b, A. Quyou a . a Laboratory of Genetics and Biometry, Faculty of Science, Ibn Tofaı¨l University, Kenitra, Morocco, b Laboratory of Pathological Anatomy and Cytology, Faculty of Health Sciences, Abdou Moumouni University, Niamey, Niger Background: Colorectal cancer is a major cause of morbidity and mortality in the world, accounting for 9.7% of all cancers. It is the third most common diagnosed cancer and the fourth leading cause of cancer-related death worldwide, causing an estimated 1.36 million new cancer cases and 694,000 deaths in 2012. We aimed to determine the epidemiological characteristics of colorectal cancer in Niger. Methods: This is a retrospective analysis of colorectal cancer cases, reported between 1992 and 2009 to the Niger Cancer Registry, established in 1992, in the Faculty of Health Sciences at the Abdou Moumouni University in Niamey, Niger. Findings: There were 349 cases diagnosed with colorectal cancer in Niger (51% of cases in the rectum and 49% in the colon), which was 4.96% of all cancers reported during the study period. Nearly 62% of the cases were in men, with a male–female ratio of 1.6. The average age at diagnosis was 46.8 ± 15.4 years. More than three-quarters (76.8%) of people diagnosed with the disease were older than 35 years at the time of diagnosis, with 63% of new cancer cases occurring in those aged 35–64 years. The highest rates for women were noted in those aged 40–69 years (62.7%) and rates for men highest between aged 35–69 years (71.2%). The risk of development of colorectal cancer varied among various ethnic groups. Djerma Sonrai was more likely to develop colorectal cancer (55%) than were any other ethnic groups, followed by Haoussa (29.5%) and Touareg (6.6%). Most colorectal cancers were adenocarcinomas and 8.6% of individuals died during the study period, accounting for 3.3% of all cancer deaths. Interpretation: Despite the limitations of the available data, it is clear that there are several barriers in access to cancer control in developing countries.
http://dx.doi.org/10.1016/j.ejca.2014.03.234
P0191 RADIATION THERAPY FOR BILIARY TRACT TUMOURS: JOINT EXPERIENCE OF THREE CENTRES M.S. Karabey a, E.Y. Erkal a, A. Yolcu b, B.H. Bakkal c, B. Sarper a, G. Aksu a, H.S. Erkal d,*. a Department of Radiation Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey, b Department of Radiation Oncology, Selcuk University Faculty of Medicine,